Eli Lilly's insulin pricing scrutiny intensifies with newly disclosed state AG probes

Fierce Pharma ------- Already under fire for its insulin pricing, Eli Lilly faces a pair of new investigations by state attorneys general. In a securities filing, Lilly disclosed that the Washington state attorney general is investigating “the pricing of our insulin products and our relationships with pharmacy benefit managers,” while the New Mexico investigation focuses solely on insulin pricing. Indianapolis-based Eli Lilly says it’s cooperating with both probes. The company’s disclosure comes shortly after the nonprofit group Type 1 Diabetes Defense Foundation sued Lilly, plus peers Sanofi and Novo Nordisk, for their insulin pricing. That suit also named as defendants top pharmacy benefit managers, which negotiate drug rebates on behalf of insurers. To learn more click on the picture below to read the article.